Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients

Travis, 2006, European evidence based consensus on the diagnosis and management of Crohn's disease: current management, Gut, 55, i16, 10.1136/gut.2005.081950b Lin, 2008, TNFalpha blockade in human diseases: an overview of efficacy and safety, Clin Immunol, 126, 13, 10.1016/j.clim.2007.08.012 Desai, 2006, Problems encountered during anti-tumour necrosis factor therapy, Best Pract Res Clin Rheumatol, 20, 757, 10.1016/j.berh.2006.06.002 Keane, 2001, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110 Malipeddi, 2007, Disseminated tuberculosis after anti-TNFalpha treatment, Lancet, 369, 162, 10.1016/S0140-6736(07)60078-6 Hoffmann, 2008, Clinical practice guideline on diagnosis and treatment of Crohn's disease, Z Gastroenterol, 46, 1094, 10.1055/s-2008-1027796 Hoffmann, 2004, Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease, Z Gastroenterol, 42, 979, 10.1055/s-2004-813510 Tissot, 2005, Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size?, Clin Infect Dis, 40, 211, 10.1086/426434 Mow, 2004, High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy, Clin Gastroenterol Hepatol, 2, 309, 10.1016/S1542-3565(04)00060-6 Dyrhol-Riise AM, Gran G, Wenzel-Larsen T, Blomberg B, Haanshuus CG, Morkve O. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis;10:57. Bocchino, 2008, Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment, Eur J Clin Microbiol Infect Dis, 27, 907, 10.1007/s10096-008-0519-1 Dyrhol-Riise, 2010, Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country, BMC Infect Dis, 10, 57, 10.1186/1471-2334-10-57 Carter, 2004, Guidelines for the management of inflammatory bowel disease in adults, Gut, 53, V1, 10.1136/gut.2004.043372 Gogus, 2010, Comparison of tuberculin skin test and QuantiFERON-TB gold in tube test in patients with chronic inflammatory diseases living in a tuberculosis endemic population, Clin Exp Med, 10, 173, 10.1007/s10238-009-0082-9 Inanc, 2009, Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis, J Rheumatol, 36, 2675, 10.3899/jrheum.090268 Kaushik, 2007, Comment on: Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience, Rheumatology (Oxford), 46, 1863, 10.1093/rheumatology/kem252 Papay, 2011, Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases, Inflamm Bowel Dis, 17, 84, 10.1002/ibd.21427 Schoepfer, 2008, Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease, Am J Gastroenterol, 103, 2799, 10.1111/j.1572-0241.2008.02050.x Seldenrijk, 1990, T-cellular immune reactions (in macrophage inhibition factor assay) against Mycobacterium paratuberculosis, Mycobacterium kansasii, Mycobacterium tuberculosis, Mycobacterium avium in patients with chronic inflammatory bowel disease, Gut, 31, 529, 10.1136/gut.31.5.529 Rowbotham, 1995, Peripheral cell-mediated immune response to mycobacterial antigens in inflammatory bowel disease, Clin Exp Immunol, 102, 456, 10.1111/j.1365-2249.1995.tb03837.x MacDonald, 1992, Cell-mediated immune injury in the intestine, Gastroenterol Clin North Am, 21, 367, 10.1016/S0889-8553(21)00036-4 Zabana, 2008, Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy, Inflamm Bowel Dis, 14, 1387, 10.1002/ibd.20496 The Robert Koch Institute, 2009, Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2008, Epidemiologisches Bulletin, 11, 83 Qumseya, 2011, QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States, Inflamm Bowel Dis, 17, 77, 10.1002/ibd.21329 Papay, 2011, Predictors of indeterminate IFN-gamma release assay in screening for latent TB in inflammatory bowel diseases, Eur J Clin Invest, 41, 1071, 10.1111/j.1365-2362.2011.02502.x